GlassScriptPhysician profile
Amarjit S Dhaliwal
NPI 1922019322
$996.84
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $17.24 · 2021: $113 · 2022: $13.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $822.76 | 2019 | |
| Pfizer INC. | $63.00 | 2021 | |
| Acrotech Biopharma INC. | $51.80 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2020 | |
| Stemline Therapeutics INC. | $16.75 | 2019 | |
| Eisai INC. | $13.37 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarjit Dhaliwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.